Looking forward, realizing the transformative potential of cGAS-STING pathway modulation in breast cancer immunotherapy requires focused efforts: Next-Generation Agonists & Delivery: Develop tumor-selective agonists (protease-activated prodrugs) and refine delivery systems (nanocarriers, localized administration) to maximize intratumoral efficacy while minimizing systemic toxicity. This evidence concerns the gene CGAS and breast carcinoma.